Passive Monitoring at Home: A Pilot Study in Parkinson Disease
- PMID: 32095766
- PMCID: PMC7015389
- DOI: 10.1159/000498922
Passive Monitoring at Home: A Pilot Study in Parkinson Disease
Abstract
We conducted a pilot study using a passive radio-wave-based home monitor in individuals with Parkinson disease (PD) with a focus on gait, home activity, and time in bed. We enrolled 7 ambulatory individuals to have the device installed in the bedroom of their homes over 8 weeks and performed standard PD assessments at baseline. We evaluated the ability of the device to objectively measure gait and time in bed and to generate novel visualizations of home activity. We captured 353 days of monitoring. Mean gait speed (0.39-0.78 m/s), time in bed per day (4.4-12.1 h), and number (1.4-5.9) and duration (15.0-49.8 min) of nightly awakenings varied substantially across and within individuals. Derived gait speed correlated well with the Movement Disorder Society-Unified Parkinson's Disease Rating Scale total (r = -0.88, p = 0.009) and motor sub-score (r = -0.95, p = 0.001). Six of the seven participants agreed that their activity was typical and indicated a willingness to continue monitoring. This technology provided promising new insights into the home activities of those with PD and may be broadly applicable to other chronic conditions.
Keywords: Gait speed; Parkinson disease; Quality of life; Sleep disorders.
Copyright © 2019 by S. Karger AG, Basel.
Conflict of interest statement
Z.K., C.S., A.G., C.-Y.H., and R.H. report no disclosures related to this paper. C.G.T. has received honoraria for speaking at American Academy of Neurology courses; research support from the Michael J. Fox Foundation, American Academy of Neurology Institute, and the National Institute of Neurological Disorders and Stroke, National Institute of Health. B.F. has received research support from the Michael J. Fox Foundation. E.R.D. has received honoraria for speaking at American Academy of Neurology courses; received compensation for consulting activities from 23 and Me, Clintrex, GlaxoSmithKline, Grand Rounds, Lundbeck, MC10, MedAvante, Medico Legal services, the National Institute of Neurological Disorders and Stroke, Shire, Teva, and UCB; research support from AMC Health, Burroughs Wellcome Fund, Davis Phinney Foundation, Duke University, GlaxoSmithKline, Great Lakes Neurotechnologies, Greater Rochester Health Foundation, Huntington Study Group, the Michael J. Fox Foundation, National Science Foundation, Patient-Centered Outcomes Research Institute, Prana Biotechnology, Raptor Pharmaceuticals, Roche, Safra Foundation, and the University of California Irvine; and stock options from Grand Rounds. D.K. has received research support from the Michael J. Fox Foundation, Novartis, and LEO Pharma.
Figures



References
-
- Stone EE, Skubic M. Unobtrusive, continuous, in-home gait measurement using the Microsoft Kinect. IEEE Trans Biomed Eng. 2013 Oct;60((10)):2925–32. - PubMed
-
- Austin D, Hayes TL, Kaye J, Mattek N, Pavel M. Unobtrusive monitoring of the longitudinal evolution of in-home gait velocity data with applications to elder care. Conference proceedings : Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual Conference. 2011;2011:6495–6498. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources